Octagon Therapeutics Receives Agilent Golden Ticket
Agilent Technologies Inc. has announced that Octagon Therapeutics have been awarded an Agilent Golden Ticket at LabCentral.
Agilent Technologies Inc. (California, USA) has announced that Octagon Therapeutics (Massachusetts, USA) have been awarded an Agilent Golden Ticket at LabCentral. The Golden Ticket provides funding for one scientist’s laboratory bench space for a year, including the benefit of LabCentral’s shared infrastructure and services.
Octagon’s mission is to discover and develop better treatments for autoimmune disease. The immune cells that drive autoimmune disease are genetically identical to healthy immune cells, but have become pathologically activated in specific ways. Octagon’s platform enables the identification of the hallmarks of immune dysregulation, allowing the precise treatment of autoimmune conditions without damaging healthy immune functioning. The ability to treat an autoimmune disease’s underlying drivers without suppressing the immune system is necessary to prevent secondary complications.
“We are thrilled to have won the Agilent Golden Ticket,” said Isaac Stoner, president and chief executive officer of Octagon Therapeutics. “Octagon has identified important new biology related to the underlying causes of autoimmune disease. The analytical chemistry expertise and instrumentation that Agilent has provided to LabCentral will be critically important as we turn these insights into new medicines, and the vibrant LabCentral community will help to shape our company culture as we grow.”
“It’s great to see Octagon awarded with Agilent’s 2021 Golden Ticket. We are excited about the potential of their autoimmune‑therapeutics platform,” said Johannes Fruehauf, co‑founder and president of LabCentral.
For more information, please visit: www.agilent.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
